| Recruiting | A Study of LCAR-HL30 in Subjects With Relapsed/Refractory Hodgkin's Lymphoma and Anaplastic Large Cell Lymphom NCT06494371 | Ruijin Hospital | Phase 1 |
| Recruiting | A Phase II Study of the Combination of Azacitidine and Pembrolizumab for Patients Relapsed/Refractory Hodgkin' NCT05355051 | M.D. Anderson Cancer Center | Phase 2 |
| Suspended | A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers NCT05337735 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | A Study of Pembrolizumab (MK-3475) in Relapsed or Refractory Classical Hodgkin's Lymphoma (rrcHL) or Relapsed NCT04875195 | Merck Sharp & Dohme LLC | Phase 2 |
| Unknown | A Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory NCT04665063 | Hebei Senlang Biotechnology Inc., Ltd. | N/A |
| Terminated | Umbralisib and Pembrolizumab in Treating Patients With Relapsed or Refractory Classical Hodgkin Lymphoma NCT03776864 | University of Washington | Phase 2 |
| Unknown | Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Clas NCT03474133 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 2 |
| Completed | A Study of Anti-PD-1 AK105 in Patients With Relapsed or Refractory Classic Hodgkin Lymphoma NCT03722147 | Akeso | Phase 1 / Phase 2 |
| Completed | The Efficacy of Salvage BGD With autoSCT Consolidation in Advanced Classical HL Patients Not Responding to ABV NCT03615664 | Polish Lymphoma Research Group | Phase 2 |
| Terminated | Use of T-allo10 in Hematopoietic Stem Cell Transplantation (HSCT) for Blood Disorders NCT03198234 | Roncarolo, Maria Grazia, MD | Phase 1 |
| Completed | A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin NCT03343652 | St. Petersburg State Pavlov Medical University | Phase 1 / Phase 2 |
| Recruiting | CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30) NCT02917083 | Baylor College of Medicine | Phase 1 |
| Completed | Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib NCT02613598 | University of Michigan Rogel Cancer Center | Phase 1 |
| Completed | Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic M NCT02576496 | Mundipharma Research Limited | Phase 1 |
| Completed | Refining a Biobehavioral Intervention to Enhance Recovery Following Hematopoietic Stem Cell Transplantation NCT02719821 | University of Wisconsin, Madison | N/A |
| Unknown | Randomized Trial of G-CSF Alone Versus Intermediate-dose Ara-C Plus G-CSF Mobilization in Hodgkin's Lymphoma o NCT02722733 | Maria Sklodowska-Curie National Research Institute of Oncology | Phase 3 |
| Completed | Adoptive Immunotherapy in Relapsed Hematological Malignancy: Early GVHD Prophylaxis NCT02593123 | Virginia Commonwealth University | Phase 2 |
| Completed | Reduced Intensity Conditioning Transplant Using Haploidentical Donors NCT02581007 | Northside Hospital, Inc. | Phase 2 |
| Completed | Study of Palifermin (Kepivance) in Persons Undergoing Unrelated Donor Allogeneic Hematopoietic Cell Transplant NCT02356159 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Early Markers of Radiation-Induced Cardiac Injury in Hodgkin Lymphoma Treated With Radiation Therapy NCT02404818 | University of Florida | — |
| Withdrawn | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) NCT02408042 | Western Regional Medical Center | Phase 1 / Phase 2 |
| Terminated | Dasatinib for Modulating Immune System After Autologous Stem Cell Transplants for Multiple Myeloma, Non-Hodgki NCT01609816 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Completed | Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies NCT02223052 | Celgene | Phase 1 |
| Recruiting | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas NCT02259556 | Chinese PLA General Hospital | Phase 1 / Phase 2 |
| Completed | Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203) NCT02208037 | National Heart, Lung, and Blood Institute (NHLBI) | Phase 2 |
| Completed | Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients NCT02164006 | TG Therapeutics, Inc. | Phase 1 |
| Completed | Bendamustine Bridge to Autologous or Allogeneic Transplant for Relapsed/Refractory Lymphoma NCT02059239 | Weill Medical College of Cornell University | Phase 1 / Phase 2 |
| Unknown | Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transpla NCT01983761 | Targazyme, Inc. | Phase 1 / Phase 2 |
| Completed | Meloxicam vs Placebo for Mobilization NCT02003625 | Massachusetts General Hospital | Phase 2 |
| Terminated | An Open-Label Study of a Novel JAK-inhibitor, INCB047986, Given in Patients With Advanced Malignancies NCT01929941 | Incyte Corporation | Phase 1 |
| Completed | A Phase II Study of Oral JAK1/JAK2 Inhibitor INC424 in Adult Patients With Relapsed/Refractory Classical Hodgk NCT01877005 | The Lymphoma Academic Research Organisation | Phase 2 |
| Completed | Trial of Haploidentical Stem Cell Transplantation for Haematological Cancers NCT01597219 | University College, London | Phase 2 |
| Recruiting | Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma NCT01788839 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies NCT01767766 | TG Therapeutics, Inc. | Phase 1 |
| Terminated | Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Mal NCT01745913 | Weill Medical College of Cornell University | Phase 2 |
| Terminated | An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istod NCT01742793 | Yale University | Phase 1 |
| Terminated | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant NCT01699581 | Greg Monohan | Phase 2 |
| Terminated | Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies NCT01643603 | Barbara Ann Karmanos Cancer Institute | Phase 1 |
| Terminated | A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives NCT01532635 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 2 |
| Completed | Brentuximab Vedotin (SGN-35) in Transplant Eligible Patients With Relapsed or Refractory Hodgkin Lymphoma NCT01508312 | Memorial Sloan Kettering Cancer Center | Phase 2 |
| Unknown | Dual Point PET Scan in Early Stage Hodgkin Lymphoma Patients With Bulky Lesions NCT01399931 | Ospedale Santa Croce-Carle Cuneo | — |
| Completed | Reduced Intensity Double Umbilical Cord Blood Transplantation NCT01408563 | Massachusetts General Hospital | Phase 2 |
| Active Not Recruiting | Communication Skills Intervention to Promote Transition Into Survivorship NCT01483664 | Memorial Sloan Kettering Cancer Center | — |
| Withdrawn | Administration of T Lymphocytes for Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma (CART CD30) NCT01316146 | UNC Lineberger Comprehensive Cancer Center | Phase 1 |
| Completed | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cycloph NCT01342289 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Phase 1 |
| Unknown | Study of Combination of PIGEV Before Autologous Stem Cell Transplant in Patients With Hodgkin's Lymphoma NCT01884428 | Armando Santoro, MD | Phase 1 |
| Unknown | Study Evaluating the Effect of R-mabHDI in Lymphocytic Predominant Hodgkin's Lymphoma NCT00816959 | American Scitech International | Phase 3 |
| Completed | FLT PET: A Pilot Study in Lymphoma Patients NCT04028804 | The Hospital for Sick Children | — |
| Unknown | Bendamustine, Gemcitabine and Vinorelbine (BeGEV) as Induction Therapy in Relapsed/Refractory Hodgkin's Lympho NCT01884441 | Armando Santoro, MD | Phase 2 |
| Completed | Whole-body MRI in Pediatric Hodgkin's Lymphoma NCT04005703 | UMC Utrecht | — |
| Active Not Recruiting | EBV CTLs Expressing CD30 Chimeric Receptors For CD 30+ Lymphoma NCT01192464 | Baylor College of Medicine | Phase 1 |
| Completed | Study of a Treatment Driven by Early PET Response to a Treatment Not Monitored by Early PET in Patients With A NCT01358747 | Centre Hospitalier Universitaire Dijon | Phase 3 |
| Terminated | Bone Marrow Transplant Using a Reduced Intensity Regimen That is Given in Two Steps NCT01350258 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | Phase 1 / Phase 2 |
| Unknown | Etoposide, Methylprednisolone, High-dose Cytarabine and Oxaliplatin (ESHAOx) for Refractory or Relapsed Hodgki NCT01300156 | National Cancer Center, Korea | Phase 2 |
| Completed | Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma NCT01169636 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | Use of Interim PET Scan to Modify Therapy in Advanced Hodgkin's Lymphoma in Order to Improve Outcomes NCT01304849 | Cancer Institute WIA | N/A |
| Completed | Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refra NCT01203020 | West Virginia University | Phase 2 |
| Completed | SNP-Based Prediction of Oral Mucositis Risk in Patients Receiving Hematopoietic Stem Cell Transplants (HSCT) NCT01402687 | Dana-Farber Cancer Institute | — |
| Completed | Tandem Auto-Allo Transplant for Lymphoma NCT01181271 | Massachusetts General Hospital | Phase 2 |
| Completed | Low Dose Chest Computed Tomography (CT) Screening NCT01180010 | University Health Network, Toronto | — |
| Completed | A Phase III Randomized, Double Blind, Placebo Controlled Multi-center Study of Panobinostat for Maintenance of NCT01034163 | Novartis Pharmaceuticals | Phase 3 |
| Completed | Mozobil for Autologous Stem Cell Mobilization NCT01164345 | Sheba Medical Center | Phase 2 |
| Completed | Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDC NCT01478191 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | Pilot Study of Radiation-Enhanced Allogeneic Cell Therapy for Progressive Hematologic Malignancy After Allogen NCT00984165 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Resminostat (4SC-201) in Relapsed or Refractory Hodgkin's Lymphoma NCT01037478 | 4SC AG | Phase 2 |
| Terminated | Study of LBH589, A Deacetylase Inhibitor in Patients With Recurrent or Refractory Hodgkin or Non-Hodgkin's Lym NCT01032148 | Roswell Park Cancer Institute | Phase 1 |
| Completed | Study of Denosumab in the Treatment of Hypercalcemia of Malignancy in Subjects With Elevated Serum Calcium NCT00896454 | Amgen | Phase 2 |
| Terminated | Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refract NCT00963495 | University Health Network, Toronto | Phase 1 |
| Completed | Endothelial Function and IMT in Survivors of Hodgkin's Lymphoma NCT00428688 | Sheba Medical Center | — |
| Terminated | Consolidation PET-based and Donor-based After Salvage Therapy in Patients With HL in Relapse or Refractory NCT00879528 | Fondazione Italiana Linfomi - ETS | — |
| Terminated | A Phase 2 Multi-Center Study of Entinostat (SNDX-275) in Patient With Relapsed or Refractory Hodgkin's Lymphom NCT00866333 | Syndax Pharmaceuticals | Phase 2 |
| Terminated | Temsirolimus for Relapsed/Refractory Hodgkin's Lymphoma NCT00838955 | Loyola University | Phase 2 |
| Terminated | Pilot Study of Abbreviated Chemotherapy Based on Positron Emission Tomography (PET) Scan in Hodgkin's Lymphoma NCT00901303 | Weill Medical College of Cornell University | N/A |
| Completed | High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and NCT00784537 | Fondazione Italiana Linfomi - ETS | Phase 2 / Phase 3 |
| Completed | A Phase 1 Study of SB1518 for the Treatment of Advanced Lymphoid Malignancies NCT00741871 | S*BIO | Phase 1 |
| Completed | Study of HCD122 in Adults With Non-Hodgkin's or Hodgkin's Lymphoma Who Have Progressed After at Least Two Prio NCT00670592 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin' NCT00792467 | Italfarmaco | Phase 1 / Phase 2 |
| Completed | Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat NCT00791011 | Amgen | Phase 1 |
| Completed | Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune S NCT00520130 | National Cancer Institute (NCI) | Phase 1 / Phase 2 |
| Completed | Positron Emission Tomography(PET) in Lymphoma Assessment NCT00887718 | University Health Network, Toronto | N/A |
| Completed | Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following NCT00510315 | Memorial Sloan Kettering Cancer Center | — |
| Completed | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Mal NCT00481871 | Acrotech Biopharma Inc. | Phase 1 / Phase 2 |
| Terminated | phII Study of an HDAC Inhibitor in Very High-risk Relapsed/Refractory Hodgkin's Lymphoma Patients NCT00496431 | Italfarmaco | Phase 1 / Phase 2 |
| Terminated | Clofarabine and Non-Myeloablative Allogeneic Hematopoietic Transplantation NCT00626626 | Milton S. Hershey Medical Center | Phase 1 / Phase 2 |
| Terminated | Study of MGCD0103 (MG-0103) in Patients With Relapsed or Refractory Hodgkin's Lymphoma NCT00358982 | Mirati Therapeutics Inc. | Phase 2 |
| Completed | Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma NCT00352027 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Hodgkin's Lymphoma NCT00359892 | Gemin X | Phase 2 |
| Unknown | Safety and Efficacy Study of TNX-650 to Treat Refractory Hodgkin's Lymphoma NCT00441818 | Tanox | Phase 1 / Phase 2 |
| Completed | Cytomegalovirus (CMV) Vaccine in Donors and Recipients Undergoing Allogeneic Hematopoietic Cell Transplant (HC NCT00285259 | Astellas Pharma Inc | Phase 2 |
| Completed | Trial of AVN-944 in Patients With Advanced Hematologic Malignancies NCT00273936 | Vertex Pharmaceuticals Incorporated | Phase 1 |
| Terminated | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies NCT00276159 | Masonic Cancer Center, University of Minnesota | Phase 2 |
| Completed | A Dose and Schedule Finding Trial With AMG 531 for Chemotherapy Induced Thrombocytopenia (CIT) in Adults With NCT00283439 | Amgen | Phase 1 / Phase 2 |
| Completed | CD8+ T Cell Depletion for GVHD Prophylaxis After Peripheral Blood Stem Cell Transplantation NCT00333190 | Dana-Farber Cancer Institute | N/A |
| Completed | Stem Cell Transplantation as Immunotherapy for Hematologic Malignancies NCT00143559 | St. Jude Children's Research Hospital | Phase 2 |
| Completed | Unrelated Donor Stem Cell Transplantation NCT01364363 | Scripps Health | N/A |
| Completed | Feasibility and Efficacy of BACOPP-21 for Patients > 60 Years With Intermediate or Advanced Hodgkins Lymphoma NCT00284271 | University of Cologne | Phase 2 |
| Completed | Pegfilgrastim PBPC Mobilization Study NCT00066092 | Amgen | Phase 2 |
| Completed | Study Evaluating the Safety and Effectiveness of ABT-510 in Subjects With Refractory Lymphoma NCT00061672 | Abbott | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of He NCT00533923 | Beth Israel Deaconess Medical Center | Phase 2 |
| Completed | Nonmyeloablative Allogeneic Transplant NCT01272817 | Scripps Health | N/A |
| Completed | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Dis NCT00388349 | Stanford University | Phase 2 |
| Completed | HD12 for Advanced Stages NCT00265031 | University of Cologne | Phase 3 |
| Completed | HD10 for Early Stages NCT00265018 | University of Cologne | Phase 3 |
| Completed | HD11 for Intermediate Stages NCT00264953 | University of Cologne | Phase 3 |
| Withdrawn | Prospective Study of Lymphoproliferative Diseases NCT01704742 | West Virginia University | — |